Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07021937 · ClinicalTrials.gov registry record · Phase 3
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
A Phase 3 study, sponsored by University of Colorado, Denver.
- Not yet
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT07021937: Clinical Trial Phase 3 study, sponsored by University of Colorado, Denver.
NCT07021937 is a Phase 3 study that has not yet begun recruiting, run by University of Colorado, Denver. The registered enrollment target is 120 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07021937, a Phase 3 study, has not yet begun recruiting, sponsored by University of Colorado, Denver.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.
Primary Outcome
measured via resting-state functional magnetic resonance imaging
Interventions
- DRUG Placebo
- DRUG Semaglutide 1.7mg subcutaneous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2031-04-30 |
| Phase | Phase 3 |
What is known before NCT07021937 opens enrollment
NCT07021937 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07021937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07021937 about?
NCT07021937 is a clinical study titled "Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity". Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible f...
What is the current status of trial NCT07021937?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2026-06-15. Estimated completion is 2031-04-30.
What interventions are being tested in trial NCT07021937?
The interventions under investigation include: Placebo (DRUG), Semaglutide 1.7mg subcutaneous (DRUG).
Who is sponsoring clinical trial NCT07021937?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07021937's enrollment target sits among peer trials
120 1619th of 2000 higher than 361 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI